Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CRMD vs NRIX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
NRIX Captures Overall Composite Edge (51.5 HOLD vs 53.2 HOLD), While CRMD Leads 4–2 on Growth & Valuation Pillars
NRIX Overall Winner
6-Pillar Tally: CRMD 4 – 2 NRIX
Matrix Metrics: CRMD 4 – 6 NRIX
As of Nov 16, 2026, Nurix Therapeutics, Inc. (NRIX) captures the overall head-to-head institutional edge over CorMedix Inc. (CRMD) on higher Unified Composite conviction (51.5/100 HOLD vs. 53.2/100 HOLD) after splitting the core matrix 6–4 (led by Growth & Scale, Profitability & Quality), while CRMD wins 4–2 across the 6-pillar growth and valuation breakdown. CRMD trades at $4.92 (49.0x Forward P/E, 41.0% operating margin) versus NRIX at $15.01 (N/M Forward P/E, 41.3% operating margin).
- Composite vs. Pillar Nuance: While CRMD currently prints a higher short-term Unified Composite Score (53.2/100 HOLD vs. NRIX 51.5/100 HOLD), NRIX captures the overall institutional head-to-head verdict (6–4 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (41.3% vs. 41.0% operating margin) and revenue trajectory (+8426.3% vs. -47.7% YoY).
- Technical & Structure Timing Caution: CRMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.3); meanwhile NRIX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About CRMD vs NRIX
CRMD
CorMedix Inc.
$4.92
+5.47% 1D
Market Cap
$384.7M
TTM Revenue
$1.05B
Forward P/E
49.0x
Beta / 30D Vol
1.20β · 107% Vol
Unified Composite Score
53.2
HOLD
Tech 60.0
Fund 60.0
Flow 69.0
Mom 55.0
Weinstein Technical Phase
Markdown · Sell / avoid
NRIX
Head-to-Head Winner
Nurix Therapeutics, Inc. Common stock
$15.01
-3.04% 1D
Market Cap
$1.7B
TTM Revenue
$702M
Forward P/E
N/M
Beta / 30D Vol
0.94β · 141% Vol
Unified Composite Score
51.5
HOLD
Tech 55.0
Fund 58.0
Flow 64.0
Mom 55.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (CRMD 4 – 2 NRIX)
1. Valuation Multiples
CRMD
Forward P/E
49.0x
N/M
Trailing P/E
2.4x
6.4x
PEG Ratio
3.79x
N/M
EV / Revenue
N/M
1.5x
2. Growth & Scale
NRIX
Revenue Growth (YoY)
-47.7%
+8426.3%
Earnings Growth (YoY)
+6.7%
+0.0%
TTM Revenue (USD)
$1.05B
$702M
Market Cap
$384.7M
$1.7B
3. Profitability & Quality
NRIX
Gross Margin
87.4%
52.4%
Operating Margin
41.0%
41.3%
Net Profit Margin
15.5%
42.0%
Return on Equity (ROE)
15.3%
44.0%
4. Balance Sheet & Cash Flow
CRMD
Cash Generation (TTM)
$785M
$370M
Cash Flow Margin
74.6%
52.7%
Net Cash / Leverage
$535M Net Cash
$655M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
CRMD
Options Structure Phase
BREAKDOWN
BREAKDOWN
Current IV / %ile
56.3% (25th %ile)
79.8% (4th %ile)
Put/Call OI Skew
0.69x (Call-Skewed)
3.05x (Put-Skewed)
OBV Trend / Tech Phase
DISTRIBUTION · Markdown
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
CRMD
OpEx & R&D Intensity
46.4% of Rev ($488M)
11.1% of Rev ($78M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
High-Margin Pricing Power Moat
High-Margin Pricing Power Moat
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: CRMD (4) vs NRIX (6)| Institutional Metric | CRMD | NRIX | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $384.7M | $1.7B | NRIX | |
| Trailing P/E Ratio | 2.4x | 6.4x | CRMD | |
| Forward P/E Ratio | 49.0x | N/M | CRMD | |
| Revenue Growth (YoY) | -47.7% | +8426.3% | NRIX | |
| Operating Margin (TTM) | 41.0% | 41.3% | NRIX | |
| Net Profit Margin | 15.5% | 42.0% | NRIX | |
| Return on Equity (ROE) | 15.3% | 44.0% | NRIX | |
| 52-Week Range Position | 3% ($5–$13) | 18% ($12–$28) | NRIX | |
| Beta / 30D Volatility | 1.20β · 107% Vol | 0.94β · 141% Vol | CRMD | |
| Unified Institutional Score | 53.2 / 100 (HOLD) | 51.5 / 100 (HOLD) | CRMD | |
| Trailing 12M Revenue (USD) | $1.05B | $702M | Scale | |
| Gross Profit Margin (TTM) | 87.4% | 52.4% | Quality | |
| PEG Ratio & EV / Revenue | 3.79x PEG · N/M EV/Rev | N/M PEG · 1.5x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $785M ($535M Net Cash) | $370M ($655M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
CRMD +6.23 pp
3M Horizon
CRMD +4.42 pp
6M Horizon
NRIX +34.64 pp
1Y Horizon
NRIX +76.92 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CRMD Revenue | NRIX Revenue | CRMD Op. Margin | NRIX Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $0M | N/A | -6250.4% | N/A | CRMD |
| FY2019 | $0M | $30M | -7416.3% | -71.5% | NRIX |
| FY2020 | $0M | $20M | -11378.4% | -364.7% | NRIX |
| FY2021 | $0M | $30M | -15417.5% | -396.3% | NRIX |
| FY2022 | $0M | $40M | -46819.9% | -476.0% | NRIX |
| FY2023 | N/A | $80M | N/A | -201.4% | NRIX |
| FY2024 | $40M | $50M | -51.4% | -390.5% | CRMD |
| FY2025 | $310M | $80M | 48.2% | -340.2% | CRMD |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
CRMD
BREAKDOWN
Current IV
56.3%
IV Percentile
25th %ile
Put/Call OI Skew
0.69x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact CRMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
NRIX
BREAKDOWN
Current IV
79.8%
IV Percentile
4th %ile
Put/Call OI Skew
3.05x (Put-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
DISTRIBUTION
Exact NRIX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
CRMD Moat Profile
High-Margin Pricing Power Moat
Biotechnology Operator
OpEx & R&D Reinvestment
46.4% of Rev ($488M)
90D Engineering Disclosures
0 Published
NRIX Moat Profile
High-Margin Pricing Power Moat
Biotechnology Operator
OpEx & R&D Reinvestment
11.1% of Rev ($78M)
90D Engineering Disclosures
0 Published
Investor FAQ CRMD vs NRIX Key Questions & Quantitative Answers
As of Nov 16, 2026, Nurix Therapeutics, Inc. (NRIX) captures the overall head-to-head institutional edge over CorMedix Inc. (CRMD) on higher Unified Composite conviction (51.5/100 HOLD vs. 53.2/100 HOLD) after splitting the core matrix 6–4 (led by Growth & Scale, Profitability & Quality), while CRMD wins 4–2 across the 6-pillar growth and valuation breakdown. CRMD trades at $4.92 (49.0x Forward P/E, 41.0% operating margin) versus NRIX at $15.01 (N/M Forward P/E, 41.3% operating margin). Composite vs. Pillar Nuance: While CRMD currently prints a higher short-term Unified Composite Score (53.2/100 HOLD vs. NRIX 51.5/100 HOLD), NRIX captures the overall institutional head-to-head verdict (6–4 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (41.3% vs. 41.0% operating margin) and revenue trajectory (+8426.3% vs. -47.7% YoY). Technical & Structure Timing Caution: CRMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.3); meanwhile NRIX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
NRIX leads the Growth & Scale pillar: CRMD posts -47.7% YoY revenue growth and +6.7% YoY earnings growth on $1.05B TTM revenue (87.4% gross margin, 41.0% operating margin), compared with NRIX at +8426.3% YoY revenue growth and +0.0% YoY earnings growth on $702M TTM revenue (52.4% gross margin, 41.3% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CRMD cumulative revenue shifted +675.0% while NRIX shifted +166.7%. In operating R&D and SG&A reinvestment, CRMD deploys 46.4% of Rev ($488M) (0 90-day corporate R&D disclosures) versus 11.1% of Rev ($78M) (0 disclosures) for NRIX.
CRMD screens cheaper on headline valuation multiples. CRMD trades at 49.0x Forward P/E, 2.4x Trailing P/E, 3.79x PEG, and N/M EV/Revenue (74.6% FCF margin), whereas NRIX trades at N/M Forward P/E, 6.4x Trailing P/E, N/M PEG, and 1.5x EV/Revenue (52.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRMD (15.3% ROE) versus NRIX (44.0% ROE) capital efficiency.
In options market volatility and institutional positioning, CRMD carries 56.3% implied volatility (25th %ile, Compressed (<25th %ile)), a 0.69x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.20β · 107% Vol realized risk). By comparison, NRIX carries 79.8% implied volatility (4th %ile, Compressed (<25th %ile)), a 3.05x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.94β · 141% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
NRIX vs CRMD · Reverse Pair
CRMD vs VTVT
· Sector Peer
CRMD vs CAPR
· Sector Peer
NRIX vs KYMR
· Sector Peer
NRIX vs RLAY
· Sector Peer
NRIX vs ORIC
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem